MassBiologics viral vector manufacturing grant (press conference highlights)

MassBiologics receives $5 million to fund viral vector manufacturingПодробнее

A Platform Production Process for Manufacturing Viral Vector and Vaccine Therapeutics Using Vero CelПодробнее

[Takara Bio] Viral vector manufacturingПодробнее

Lifecycle MA - Press Announcement Brammer BioПодробнее

Viral Vector Process Development Summit | Oxford Biomedica Solutions InterviewПодробнее

MassBiologics: 125 Years of improving public heathПодробнее

Producing Viral Vectors for Clinical Trials With On-Site Clinical Manufacturing FacilityПодробнее

Australia's first commercial scale viral vector manufacturing facilityПодробнее

Innovations in viral vector development, scale up and production webinarПодробнее

New Leadership at UMass BiologicsПодробнее

Viral Vector Production for Gene Therapy: Introduction and Downstream Purification & FillingПодробнее

Non-Viral Vector Design and ProductionПодробнее

Microinjection-Viral Vectors Expressing Cre Recombinase: Role-Target Genes l Protocol PreviewПодробнее

Enabling Large-Scale Production of Viral Vectors in the Gibco™ CTS LV-MAX Lentiviral....Подробнее

Find Your Purpose in Viral Vector ServicesПодробнее

Mireli Fino takes the helm at MassBiologicsПодробнее

The current landscape of viral vector-based gene therapyПодробнее

Scientific Symposium 305 Designing the Next Generation of Viral Vectors Organized by the Viral GeПодробнее

Challenges in manufacturing viral vectors for the clinicПодробнее